Hong Kong stock anomaly | Junshi Biosciences (01877.HK) rose nearly 3%, exploring new indications for frontline treatment of HER2-expressing urothelial carcinoma accepted for review

According to the China Finance app, Junshi Biosciences (01877.HK) has increased by nearly 3%, as of the time of publication, it has increased by 1.62% to HK $25.14, with a trading volume of HK $5.4237 million.